Elham Rastegari1,2,3, Yu-Jer Hsiao1,3, Wei-Yi Lai1,2,3, Yun-Hsien Lai1,2,3, Tien-Chun Yang1,2,3, Shih-Jen Chen1,4, Pin-I Huang5, Shih-Hwa Chiou1,2,3,4, Chung-Yuan Mou6, Yueh Chien1,2,3. 1. Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan. 2. Institute of Pharmacology, National Yang-Ming Chiao Tung University, Taipei 11217, Taiwan. 3. School of Medicine, National Yang-Ming Chiao Tung University, Taipei 11217, Taiwan. 4. Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 11217, Taiwan. 5. Department of Oncology, Taipei Veterans General Hospital, Taipei Veterans General Hospital, Taipei 11217, Taiwan. 6. Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Abstract
The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.
The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart pan class="Chemical">mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.
Authors: Hanaa Ali Hussein; Muhammad Shahid Nazir; Nizakat Azra; Zeenat Qamar; Azman Seeni; Tengku Ahmad Damitri Al-Astani Tengku Din; Mohd Azmuddin Abdullah Journal: Mar Drugs Date: 2022-07-27 Impact factor: 6.085